Definition/General

Introduction:
-Vaginal clear cell adenocarcinoma (VCCA) is a rare malignant tumor accounting for 5-10% of primary vaginal cancers
-It is strongly associated with in utero diethylstilbestrol (DES) exposure
-VCCA is characterized by clear cells with hobnail morphology and tubulocystic architecture
-It typically occurs in younger women compared to other vaginal cancers
-The tumor has a unique histological appearance that is diagnostic when recognized.
Origin:
-Originates from müllerian remnants within the vaginal wall, specifically from mesonephric duct remnants
-DES exposure during fetal development leads to persistence of müllerian epithelium in the vagina
-The tumor develops from these ectopic glandular epithelial rests
-Vaginal adenosis (benign glandular epithelium) is often present adjacent to the tumor
-The neoplastic transformation occurs through malignant change in these displaced epithelial elements.
Classification:
-WHO classification recognizes clear cell adenocarcinoma as a distinct entity
-Architectural patterns include tubulocystic, solid, and papillary
-Cytological patterns include clear cell and hobnail variants
-FIGO staging follows the same system as other vaginal cancers
-Grade is typically considered high-grade due to the clear cell morphology
-Molecular classification based on genetic alterations is emerging.
Epidemiology:
-Peak incidence in 3rd-4th decades (20-40 years), much younger than other vaginal cancers
-Strong association with DES exposure in utero (risk increased 40-fold)
-DES daughters have 1 in 1,000 risk of developing VCCA
-Incidence has decreased significantly since DES was banned in 1971
-Non-DES cases occur in older women and are extremely rare
-Family clustering has been reported in some cases.

Clinical Features

Presentation:
-Abnormal vaginal bleeding (90% of cases), often the first symptom
-Vaginal discharge (clear, watery, or bloody)
-Pelvic pain and discomfort
-Dyspareunia and post-coital bleeding
-Palpable vaginal mass in advanced cases
-Urinary symptoms (frequency, urgency) with anterior wall involvement
-Bowel symptoms (constipation, tenesmus) with posterior wall involvement.
Symptoms:
-Intermenstrual bleeding or menorrhagia in premenopausal women
-Post-coital bleeding (common early symptom)
-Watery vaginal discharge with characteristic clear appearance
-Pelvic pressure and fullness sensation
-Deep dyspareunia due to tumor location
-Urinary incontinence or retention in advanced cases
-Rectal bleeding with rectovaginal involvement
-Lower extremity edema from lymphatic obstruction.
Risk Factors:
-In utero DES exposure (strongest risk factor, 95% of cases in young women)
-Maternal DES treatment during pregnancy (1940-1971)
-Age 15-35 years for DES-associated cases
-Presence of vaginal adenosis (benign precursor lesion)
-Family history of DES exposure
-Clear cell adenocarcinoma in other sites (cervix, endometrium)
-Non-DES cases: advanced age, immunosuppression.
Screening:
-DES daughters require lifelong annual surveillance starting at menarche or age 14
-Annual pelvic examination with careful inspection of vagina
-Pap smear with special attention to glandular cells
-Colposcopy for any suspicious lesions or positive cytology
-Biopsy of any visible abnormality
-Iodine staining may help identify adenosis
-Patient education about symptoms and self-examination.

Master Vaginal Clear Cell Adenocarcinoma Pathology with RxDx

Access 100+ pathology videos and expert guidance with the RxDx app

Gross Description

Appearance:
-Polypoid or nodular growth with smooth, glistening surface
-Clear to gray-white coloration with translucent appearance
-Firm to soft consistency depending on cystic component
-Multinodular surface with irregular contours
-Cystic areas containing clear fluid
-Hemorrhage may be present in larger tumors
-Ulceration is uncommon in early lesions.
Characteristics:
-Smooth, lobulated surface resembling clear cell morphology macroscopically
-Translucent appearance due to glycogen-rich clear cells
-Cut surface shows solid and cystic areas
-Clear fluid exuding from cystic spaces
-Soft, gelatinous consistency in areas with prominent clear cells
-Firm areas corresponding to stromal desmoplasia
-Minimal surface ulceration compared to squamous cell carcinoma.
Size Location:
-Size ranges from small nodules (1-2 cm) to large masses (up to 10 cm)
-Upper third of vagina most commonly affected (80-90%)
-Anterior and lateral walls more frequently involved
-Multifocal disease in 10-15% of cases
-Involvement of vaginal fornices common in upper third tumors
-Cervical involvement must be excluded for primary vaginal diagnosis.
Multifocality:
-Multifocal presentation more common than in other vaginal cancers (10-15%)
-Skip lesions may be present along vaginal canal
-Associated adenosis (benign glandular epithelium) often surrounds the tumor
-Bilateral distribution can occur in extensive cases
-Concurrent cervical clear cell adenocarcinoma in some DES-exposed patients.

Microscopic Description

Histological Features:
-Clear cells with abundant clear, glycogen-rich cytoplasm and distinct cell membranes
-Hobnail cells with enlarged nuclei protruding into glandular lumens
-Tubulocystic architecture with round to oval glands and cysts
-Solid areas with sheets of clear cells
-Papillary pattern with fibrovascular cores
-Hyalinized stroma with desmoplastic response.
Cellular Characteristics:
-Large cells with voluminous clear cytoplasm due to glycogen accumulation
-Distinct cell membranes creating honeycomb appearance
-Enlarged nuclei with irregular contours and prominent nucleoli
-Hobnail morphology with nuclei protruding into luminal spaces
-Mitotic activity variable but usually evident
-Eosinophilic cells may be admixed with clear cells.
Architectural Patterns:
-Tubulocystic pattern (most common) with round glands and cystic spaces
-Solid pattern with sheets and nests of clear cells
-Papillary pattern with complex papillae and fibrovascular cores
-Mixed patterns commonly present in same tumor
-Invasive growth into vaginal stroma with irregular infiltration
-Lymphovascular invasion may be present.
Grading Criteria:
-Clear cell adenocarcinoma is typically considered high-grade by definition
-Nuclear grade based on nuclear size, irregularity, and nucleolar prominence
-Mitotic count usually elevated (>5-10 per 10 HPF)
-Architectural complexity with loss of glandular organization
-Solid growth pattern indicates higher grade
-Necrosis may be present in high-grade areas.

Immunohistochemistry

Positive Markers:
-PAX8 (nuclear, positive in 80-90% of cases)
-CK7 (cytoplasmic, diffusely positive)
-Napsin A (cytoplasmic, positive in 70-80% of cases)
-CA125 (cytoplasmic and luminal, positive)
-ER (nuclear, positive in 30-50% of cases)
-EMA (cytoplasmic and luminal, positive)
-Hepatocyte nuclear factor-1β (HNF1β) (nuclear, positive).
Negative Markers:
-WT1 (negative, helps exclude serous adenocarcinoma)
-p53 (wild-type pattern, not overexpressed)
-CK20 (negative, helps exclude gastrointestinal origin)
-CDX2 (negative, excludes intestinal differentiation)
-TTF-1 (negative, excludes lung metastasis)
-RCC marker (negative, excludes renal cell carcinoma)
-Inhibin (negative, excludes sex cord-stromal tumors).
Diagnostic Utility:
-PAX8 positivity supports müllerian origin
-Napsin A positivity is characteristic of clear cell adenocarcinoma
-CK7+/CK20- pattern consistent with gynecological origin
-HNF1β expression is highly characteristic of clear cell adenocarcinoma
-ER negativity or weak positivity distinguishes from endometrioid adenocarcinoma
-WT1 negativity helps exclude serous adenocarcinoma.
Molecular Subtypes:
-DES-associated type (younger patients, better prognosis, specific genetic profile)
-Sporadic type (older patients, worse prognosis, different genetic alterations)
-Lynch syndrome-associated (rare cases with mismatch repair deficiency)
-ARID1A-deficient subtype (loss of ARID1A expression)
-PI3K-activated subtype (PIK3CA mutations or PTEN loss).

Molecular/Genetic

Genetic Mutations:
-ARID1A mutations (50-70% of cases, tumor suppressor gene)
-PIK3CA mutations (30-50% of cases, oncogene activation)
-PTEN mutations (20-30% of cases, tumor suppressor loss)
-KRAS mutations (15-25% of cases)
-TP53 mutations (rare in clear cell adenocarcinoma, <10%)
-PPP2R1A mutations (specific to clear cell carcinomas, 10-15%)
-TERT promoter mutations (subset of cases).
Molecular Markers:
-ARID1A loss by immunohistochemistry (correlates with mutations)
-PI3K pathway activation (pAKT, pmTOR expression)
-HNF1β overexpression (transcription factor, characteristic of clear cell)
-Napsin A expression (lysosomal protein, diagnostic marker)
-p53 wild-type pattern (unlike serous adenocarcinoma)
-Mismatch repair proteins (intact in most cases).
Prognostic Significance:
-DES exposure status (DES-associated cases have better prognosis)
-Age at diagnosis (younger patients do better)
-Stage at presentation (most important prognostic factor)
-Tumor size (<2 cm associated with better survival)
-ARID1A status (loss may predict response to certain therapies)
-PI3K pathway status (activation associated with drug resistance).
Therapeutic Targets:
-PI3K/AKT/mTOR pathway (mTOR inhibitors, PI3K inhibitors)
-ARID1A deficiency (synthetic lethality with EZH2 inhibitors)
-DNA damage response (PARP inhibitors in homologous recombination deficient cases)
-Angiogenesis (bevacizumab in recurrent disease)
-Immunotherapy (PD-1/PD-L1 inhibitors in select cases)
-HNF1β-dependent pathways (novel therapeutic approaches under investigation).

Differential Diagnosis

Similar Entities:
-Renal cell carcinoma metastasis (clear cell morphology, but RCC markers positive)
-Vaginal endometrioid adenocarcinoma (glandular, but different cytology)
-Metastatic clear cell adenocarcinoma from ovary or endometrium
-Yolk sac tumor (clear cell areas, but different age and markers)
-Vaginal adenosis (benign glandular epithelium)
-Arias-Stella reaction (pregnancy-related changes).
Distinguishing Features:
-VCCA vs RCC metastasis: PAX8+/Napsin A+ vs RCC marker+/CD10+
-VCCA vs endometrioid: Clear cells/hobnail vs eosinophilic cells, ER usually negative vs positive
-VCCA vs yolk sac tumor: Age (reproductive vs pediatric), AFP negative vs positive
-VCCA vs adenosis: Nuclear atypia and mitoses vs bland cytology
-Primary vs metastatic: Clinical correlation and imaging studies essential.
Diagnostic Challenges:
-Small biopsy interpretation may be limited by sampling and crush artifact
-Distinguishing from adenosis requires careful attention to nuclear features
-Determining primary site when multiple clear cell adenocarcinomas present
-DES history may not be available or known to patient
-Rare occurrence may lead to unfamiliarity with morphology
-Mixed patterns within tumor may complicate diagnosis.
Rare Variants:
-Oxyphilic variant (eosinophilic rather than clear cytoplasm)
-Cystic variant (predominantly cystic architecture)
-Solid variant (predominantly solid growth pattern)
-Mixed müllerian tumor (clear cell adenocarcinoma with mesenchymal elements)
-Clear cell adenofibroma (benign counterpart with fibromatous stroma)
-Atypical proliferative (borderline) clear cell tumor (low malignant potential).

Sample Pathology Report

Template Format

Sample Pathology Report

Complete Report: This is an example of how the final pathology report should be structured for this condition.

Specimen Information

Vaginal biopsy/excision from [location] measuring [size] cm

Diagnosis

Clear cell adenocarcinoma of vagina

Classification

Clear cell adenocarcinoma with [predominant architectural pattern]

Histological Features

Shows clear cells with hobnail morphology, [tubulocystic/solid/papillary] architecture, and nuclear atypia

Invasion and Extent

Depth of invasion: [X] mm, extent: [superficial/deep stromal/paravaginal]

Margins

Margins are [involved/uninvolved], closest margin [X] mm from tumor

Lymphovascular Invasion

Lymphovascular invasion: [present/absent]

Special Studies

PAX8: [positive/negative], Napsin A: [positive/negative], CK7: [positive/negative]

HNF1β: [positive/negative], CA125: [positive/negative]

ER: [positive/negative/weak], Ki-67 index: [percentage]%

Clinical Correlation

DES exposure history: [known/unknown/negative], Age: [X] years

FIGO Staging

FIGO Stage: [I/II/III/IV] - [staging description]

Prognostic Factors

DES status: [associated/sporadic], Age: [X] years, Stage: [I/II/III/IV], Size: [X] cm

Final Diagnosis

Primary vaginal clear cell adenocarcinoma, FIGO Stage [I/II/III/IV]